Evidence-based procedures to improve the reliability of circulating miRNA biomarker assays.

Publication Title

Clinical chemistry and laboratory medicine : CCLM / FESCC

Authors

Sarah R Greytak
Kelly B Engel
Dave S B Hoon, Department of Translational Molecular Medicine & Sequencing Center, Saint Johns' Cancer Institute, Providence Health and Service, Santa Monica, CA, USAFollow
Kevin M Elias
Christina M Lockwood
Ping Guan
Helen M Moore

Document Type

Article

Publication Date

5-3-2023

Keywords

california; sjci; santa monica; genomics; cell-free miRNA; evidence-based guidance; plasma; preanalytical variability; serum; standard operating procedure

Abstract

Circulating cell-free microRNAs (cfmiRNA) are an emerging class of biomarkers that have shown great promise in the clinical diagnosis, treatment, and monitoring of several pathological conditions, including cancer. However, validation and clinical implementation of cfmiRNA biomarkers has been hindered by the variability introduced during different or suboptimal specimen collection and handling practices. To address the need for standardization and evidence-based guidance, the National Cancer Institute (NCI) developed a new Biospecimen Evidenced-Based Practices (BEBP) document, entitled "Cell-free miRNA (cfmiRNA)

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

DOI

10.1515/cclm-2023-0131